Verflixt! Es sieht so aus, als wenn Sie einen veralteten Browser benutzen. Wir empfehlen Ihnen dringend Ihren Browser zu aktualisieren.
Weitere Informationen über Browser und Updates finden Sie hier

IMP - Research Institute of Molecular Pathology

The Research Institute of Molecular Pathology (IMP) is a leading, nonprofit research institute committed to pushing the frontiers of biomedical science. Since its foundation in 1988, the IMP has created a legacy of research excellence and academic eminence. The IMP is largely sponsored by the pharmaceutical company Boehringer Ingelheim, yet is fully independent in its governance and research programs. The IMP provides its scientists with the resources and freedom they need to follow their own scientific instincts and ideas. Together with Max F. Perutz Laboratories (MFPL),  the Institute of Molecular Biotechnology (IMBA),  the Gregor Mendel Institute (GMI) of the Austrian Academy of Science and several Biotech companies, the IMP forms the Campus Vienna Biocenter. The IMP shares scientific and administrative services with IMBA and GMI and together with the partners at the campus also operates a publicly-funded scientific support facility, the CSF. We strongly believe that a supportive and collaborative intellectual culture is essential to attract creative and bold scientists, willing to cross the boundaries of their discipline in pursuite of groundbreaking scientific discoveries.  Jan-Michael Peters         &     Harald Isemann Acting Scientific Director        Administrative Director  

Details


Adresse:
IMP - Research Institute of Molecular Pathology

Dr. Bohr-Gasse 7
1030 Wien
Österreich
Arbeitsgebiet:
Klinische Forschung
Forschung & Entwicklung
Expansion:
national
Webseite: